Emerging Strategies in the Management of Genitourinary Cancers – Live

Description

Program Description

---

Click to Go to the Event Registration

The treatment of genitourinary malignancies has dramatically evolved over recent years. Renal cell carcinoma, urothelial carcinoma of the bladder, and prostate adenocarcinoma are the commonly encountered genitourinary malignancies and represent a heterogeneous population of cancers in both histology and approach to treatment. However, all three cancers have undergone paradigm shifts in their respective therapeutic landscapes due to a greater understanding of their underlying molecular mechanisms and oncogenic drivers.

Agenda

---

• Pretest Clinical Vignettes – 1
• Discuss the therapeutic potential of multitargeted kinase inhibitors and combinations in metastatic renal cell carcinoma
• Posttest Clinical Vignettes –1
• Pretest Clinical Vignettes – 2
• Efficacy and safety of novel combinations of ADT and androgen axis inhibitors in patients with metastatic prostate cancer
• Posttest Clinical Vignettes – 2
• Pretest Clinical Vignettes – 3
• Discuss the efficacy and safety of antibody-drug conjugate (ADC), immunotherapy, and fibroblast growth factor receptor (FGFR) based therapies in patients with metastatic urothelial carcinoma
• Posttest Clinical Vignettes – 3
• Audience Questions and Panel Discussion

Intended Audience

---

Hematologists/oncologists, urologists, nurse practitioners, physician assistants, and nurses involved in the care and treatment of patients with genitourinary cancers such as prostate cancer, renal cell carcinoma, and urothelial carcinoma.

Commercial Supporter

---

This activity is supported by an independent educational grant from Exelixis, Inc.